They have developed new nanorobotic agents capable of navigating through the bloodstream to administer a drug with precision by specifically targeting the active cancerous cells of tumors.

Roche meanwhile already has the comfort of one positive result for giredestrant from the coopERA study in post-menopausal women with hormone receptor-positive, HER2-negative early breast cancer ...